STAR IN THE NEWS
Press Releases
- PNAV Digital
- October 23, 2026
SOUTH SAN FRANCISCO, CA, October 23, 2026 – Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary...
- Incyte
- July 6, 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 6, 2026-- Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD)...
- Incyte
- June 8, 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 8, 2026-- Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones...
News Coverage
- Lei Lei Wu, Endpoints News
- December 7, 2025
ORLANDO, Fla. — Star Therapeutics said its once-a-month injection for von Willebrand disease substantially cut bleeding rates in a preliminary study, and is thinking about the next moves to complete a larger trial and eventually get the drug to patients. The trial data released Saturday looked at eight patients, and showed that treatment with Star’s shot decreased bleeds by a...
- Darren Incorvaia, Fierce Biotech
- December 7, 2025
ORLANDO, Fla. — With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039. In a phase 1/2 trial in von Willebrand disease (VWD), the molecule substantially reduced bleeding in eight patients. “We're seeing significant reductions in bleeds across all types of VWD and all types of bleeds,” Star founder...
- BiotechTV
- December 6, 2025
Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.
- Kyle LaHucik, Endpoints News
- September 30, 2025
Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and get its sole clinical-stage drug most of the way through a Phase 3 trial in von Willebrand disease while also expanding into other disorders, CEO...
- Gwendolyn Wu, BioPharma Dive
- September 30, 2025
The biotech began Phase 3 testing of an experimental medicine for Von Willebrand disease in early September. Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing. Initially formed as a “hub-and-spoke” biotech intending to build single-drug offshoots, Star is now primarily focused on a singular program for...
- Zoey Becker, Fierce Biotech
- September 30, 2025
A hefty $125 million in new financing has been written in the stars for Star Therapeutics through an oversubscribed series D funding round. The series D was co-led by Sanofi Ventures and Viking Global Investors, with support from over a dozen existing investors including Sofinnova, Blue Owl Capital and RA Capital Management. New investors such as Janus Henderson...
- Jules Adam, Labiotech
- January 9, 2025
Earlier this week, Star Therapeutics’ von Willebrand disease candidate – VGA039 – was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). While it is the most common inherited bleeding disorder and affects about 1% of the population, you don’t hear about von Willebrand disease every day. With Star Therapeutics’ candidate getting some recognition from the FDA...
Presentations
- Purohit Navigation
- December 6, 2025
ASH 2025 ABSTRACT #308
